A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Oral Inactivated Whole Cell Shigella Flexneri 2a Vaccine in Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2012
At a glance
- Drugs Shigella flexneri 2A vaccine (Primary)
- Indications Shigella infections
- Focus Adverse reactions
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2012 Planned End Date changed from 1 Sep 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 10 Jul 2012 Planned End Date changed from 1 Nov 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.